Digestive Diseases and Sciences

, Volume 63, Issue 6, pp 1541–1550 | Cite as

Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers

  • Neha Berry
  • Saroj Kant Sinha
  • Anish Bhattacharya
  • K. K. Prasad
  • Chetana Vaishnavi
  • Kim Vaiphei
  • Jayanta Samanta
  • Raghavendra Prasada
  • Narendra Dhaka
  • Rakesh Kochhar
Original Article



Disease activity in ulcerative colitis (UC) is best assessed clinically by Mayo score. 18-Fluorodeoxyglucose positron emission tomography-computerized tomography (FDG PET-CT) is a noninvasive imaging technique to assess extent, disease activity and response to treatment of UC, especially in high risk population or patients unwilling for endoscopy.


We conducted a prospective observational study with the aim of assessing and correlating UC disease activity by clinical criteria, endoscopy, histology, serum and fecal biomarkers, and FDG PET-CT.


Sixty eligible patients of UC were enrolled into three groups (26 remission, 24 moderate and 10 severe activity) as per Mayo score and FDG PET-CT was performed within 72 h of colonoscopy. ESR, CRP, and fecal calprotectin (FC) levels were determined for all patients.


Of 60 enrolled patients, 10% patients had proctitis, 43.3% left-sided colitis, and 46.7% extensive colitis. ESR, CRP, FC levels, and rectal PET activity were significantly higher in groups with moderate and severe disease activity. Rectal PET activity showed a significant correlation with the Mayo score (k = 0.465, p < 0.001), endoscopic subscore (k = 0.526, p < 0.001), histological score (k = 0.496, p < 0.001), and FC (k = 0.279, p = 0.031). Extent evaluation by FDG PET-CT and colonoscopy showed a significant correlation (k = 0.582, p < 0.001). Besides, FDG PET-CT identified sacroiliitis in one patient and adenocarcinoma in one patient.


FDG PET-CT is a reliable noninvasive tool for detection of disease activity, extent in UC with good correlation with Mayo score, histology and fecal biomarkers and accurate predictor of disease remission.


Ulcerative colitis Positron emission tomography Fecal calprotectin Endoscopy 



Ulcerative colitis


Inflammatory bowel disease


Crohn’s disease


Clostridium difficile toxin assay


Fecal calprotectin


Positron emission tomography with 18-fluorodeoxyglucose


Author’s contribution

NB helped in literature search, figures, study design, data collection, data analysis, data interpretation, and writing. SKS involved in study design, data analysis, and data interpretation. AB helped in study design, data collection, data analysis, and PET-CT scans. KKP involved in histopathological analysis. CV helped in biochemical tests, stool tests, data collection, and data analysis. KV helped in histopathological analysis. JS involved in data collection, data analysis, and data interpretation. RP involved in data collection. ND helped in data interpretation. RK involved in study design, data analysis, and data interpretation.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10620_2018_5026_MOESM1_ESM.docx (36 kb)
Supplementary material 1 (DOCX 36 kb)
10620_2018_5026_MOESM2_ESM.tif (334 kb)
Supplementary material 2 (TIFF 333 kb)
10620_2018_5026_MOESM3_ESM.tif (342 kb)
Supplementary material 3 (TIFF 342 kb)
10620_2018_5026_MOESM4_ESM.tif (325 kb)
Supplementary material 4 (TIFF 324 kb)
10620_2018_5026_MOESM5_ESM.tif (249 kb)
Supplementary material 5 (TIFF 249 kb)


  1. 1.
    Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52:1587–1590.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.CrossRefPubMedGoogle Scholar
  3. 3.
    Zisman TL, Rubin DT. Novel diagnostic and prognostic modalities in inflammatory bowel disease. Gastroenterol Clin North Am. 2009;38:729–752.CrossRefPubMedGoogle Scholar
  4. 4.
    Treglia G, Quartuccio N, Sadeghi R, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis. J Crohns Colitis. 2013;7:345–354.CrossRefPubMedGoogle Scholar
  5. 5.
    Lemberg DA, Issenman RM, Cawdron R, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:733–738.CrossRefPubMedGoogle Scholar
  6. 6.
    Das CJ, Makharia GK, Kumar R, et al. PET/CT colonography: a novel non-invasive technique for assessment of extent and activity of ulcerative colitis. Eur J Nucl Med Mol Imaging. 2010;37:714–721.CrossRefPubMedGoogle Scholar
  7. 7.
    Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–813.CrossRefGoogle Scholar
  8. 8.
    Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroentérol Clin Biol. 2009;33(Suppl 3):S158–S173.CrossRefPubMedGoogle Scholar
  9. 9.
    General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81:14–18.Google Scholar
  10. 10.
    Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis. Inflamm Bowel Dis. 2008;14:1660–1666.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Geboes KA. Reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–409.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ahmadi A, Li Q, Muller K, et al. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography enterography in active Crohnʼs disease. Inflamm Bowel Dis. 2010;16:974–981.CrossRefPubMedGoogle Scholar
  13. 13.
    Rubin DT, Surma BL, Gavzy SJ, et al. Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis. 2009;15:750–755.CrossRefPubMedGoogle Scholar
  14. 14.
    Saboury B, Salavati A, Brothers A, et al. FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging. 2014;41:605–614.CrossRefPubMedGoogle Scholar
  15. 15.
    Sipponen T, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn’s disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012;47:778–784.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Neha Berry
    • 1
  • Saroj Kant Sinha
    • 1
  • Anish Bhattacharya
    • 2
  • K. K. Prasad
    • 1
  • Chetana Vaishnavi
    • 1
  • Kim Vaiphei
    • 3
  • Jayanta Samanta
    • 1
  • Raghavendra Prasada
    • 1
  • Narendra Dhaka
    • 1
  • Rakesh Kochhar
    • 1
  1. 1.Department of Gastroenterology, Postgraduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Department of Nuclear Medicine, Postgraduate Institute of Medical Education and ResearchChandigarhIndia
  3. 3.Department of Histopathology, Postgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations